Skip to content

partnerships

Showing posts for the tag 'partnerships'

Show all
Ultromics Secures Strategic Investment from the American Heart Association’s Go Red for Women Venture Fund

Ultromics Secures Strategic Investment from the American Heart Association’s Go Red for Women Venture Fund

Ultromics receives an investment from the AHA Go Red for Women Venture Fund to address heart failure with preserved ejection fraction, a condition affecting millions of women.
Ultromics Study Shows AI Could Improve Early Detection of Cardiac Amyloidosis

Ultromics Study Shows AI Could Improve Early Detection of Cardiac Amyloidosis

Ultromics’ new multi-center study shows its AI tool, EchoGo® Amyloidosis, can improve early detection of cardiac amyloidosis using routine heart ultrasounds, increasing referral accuracy and reducing unnecessary testing—helping more patients access life-saving therapies sooner.
Ultromics named a WIRED 2025 Trailblazer

Ultromics named a WIRED 2025 Trailblazer

Ultromics has been named a WIRED 2025 Trailblazer, recognized for pioneering AI in cardiovascular imaging. With its FDA-cleared EchoGo® platform, Ultromics is tackling the global heart failure crisis by enabling earlier diagnosis and transforming patient care.
Ultromics selected for the Tech Nation’s Future Fifty 2025 programme

Ultromics selected for the Tech Nation’s Future Fifty 2025 programme

Ultromics has been selected for Tech Nation’s prestigious Future Fifty 2025 programme, recognizing its AI-powered cardiovascular imaging platform, EchoGo®. Founded at the University of Oxford, Ultromics is scaling globally to close critical gaps in heart failure diagnosis and improve early detection across leading healthcare institutions.
Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale

Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale

New $55M Series C round fuels Ultromics' nationwide rollout of FDA-cleared AI that detects heart failure earlier from a single echo scan—helping clinicians catch HFpEF and cardiac amyloidosis before it's too late.
Landmark Study Shows Ultromics’ EchoGo® Amyloidosis Significantly Improves Detection of Cardiac Amyloidosis with Echocardiography

Landmark Study Shows Ultromics’ EchoGo® Amyloidosis Significantly Improves Detection of Cardiac Amyloidosis with Echocardiography

New study shows EchoGo® Amyloidosis, developed by Ultromics, Mayo Clinic and University of Chicago Medicine, detects cardiac amyloidosis with accuracy for a single echo view
Ultromics Introduces AI-Powered Probability Scoring on EchoGo® Heart Failure for Enhanced HFpEF Diagnosis

Ultromics Introduces AI-Powered Probability Scoring on EchoGo® Heart Failure for Enhanced HFpEF Diagnosis

EchoGo® Heart Failure now delivers a continuous probability score reflecting the likelihood of HFpEF to support clinical decision-making.
CMS Updates Final Outpatient Clinical APC Rule for Ultromics’ EchoGo® Heart Failure

CMS Updates Final Outpatient Clinical APC Rule for Ultromics’ EchoGo® Heart Failure

EchoGo® Heart Failure assigned to APC 5743 under the new Category III CPT code 0932T for outpatient HFpEF diagnosis
Ultromics obtains Breakthrough Device FDA clearance for its Cardiac Amyloidosis screening device through the Total Product Lifecycle Advisory Program

Ultromics obtains Breakthrough Device FDA clearance for its Cardiac Amyloidosis screening device through the Total Product Lifecycle Advisory Program

Ultromics granted FDA Breakthrough Device Designation for its Amyloidosis device
Ultromics announces partnership to expedite development of Echo AI algorithm for earlier detection of cardiac amyloidosis

Ultromics announces partnership to expedite development of Echo AI algorithm for earlier detection of cardiac amyloidosis

New partnership with Pfizer will expedite the development of an Echo AI algorithm for the early detection of Cardiac Amyloidosis.
Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detection

Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detection

Ultromics granted FDA Breakthrough Device Designation for its Amyloidosis device
Wolverhampton NHS cardiologists to use new cloud technology to interpret echocardiograms

Wolverhampton NHS cardiologists to use new cloud technology to interpret echocardiograms

Cardiologists in Wolverhampton will be the first in the Midlands to use innovative digital technology in a key diagnostic test for heart disease. Red more.

Curious about upcoming research and innovation?

Sign-up to hear about the latest news.

 

Sign up to newsletter

mail
534518

cases processed